baber/WOPTO huggingface dataset:
Patent NZ-572071-A (NZ)
Title: Inhibitors of c-fms kinase
Inventor: CHEN JINSHENG
IPC: A61P35/00
Filed: 2007-04-18
Abstract: Disclosed are compounds of Formula I or a solvate, hydrate, tautomer of pharmaceutically acceptable salt thereof, wherein J is CH or N and the remaining substituents are as defined in the specification, pharmaceutical compositions comprising said compounds and their use in treating diseases such as inflammation, cancer and cardiovascular disease. Also disclosed is their use as protein tyrosine kinase inhibitors and c-fms kinase inhibitors.
Patent NZ-577933-A (NZ)
Title: Polyelectrolyte precipitation and purification of antibodies
Inventor: FAHRNER ROBERT L
IPC: A61K31/198
Filed: 2008-01-10
Abstract: Disclosed is a method of purifying antibodies. The disclosed method comprises: a) adjusting the acidity or salt concentration of a mixture containing an antibody wherein the antibody is derived from a harvested cell culture fluid; b) adding a negatively charged polyelectrolyte selected from polyvinylsulfonic acid, polyvinylsulfonate, and polystyrenesulfonic acid, wherein the negatively charged polyelectrolyte has sulfonic acid or carboxylic acid functionality, a molecular weight of 1200 to 1,100,000 Da, and a concentration between 0.01% to 1.0% weight/volume in the mixture containing the antibody, whereby a protein-polyelectrolyte precipitate is formed; c) separating the protein-polyelectrolyte precipitate from impurities selected from protein aggregates, protein fragments, host cell proteins, insulin, gentamicin, DNA, and leached protein A; d) isolating the protein-polyelectrolyte precipitate; e) resuspending the protein-polyelectrolyte precipitate in an aqueous solution; and f) separating the polyelectrolyte from the purified antibody by anion-exchange chromatography of the resuspended protein-polyelectrolyte precipitate.
Patent NZ-578716-A (NZ)
Title: A method of identification of cells that show sensitivity to modulation of signaling mediated by a fibroblast growth factor receptor or a variant thereof
Inventor: GRAUS PORTA DIANA
IPC: G01N33/574
Filed: 2008-02-25
Abstract: Disclosed is a method of disease identification in a biological sample by identifying if a disease will be responsive to FGF-R inhibition via identifying the presence of a tyrosine phosphorylated form of FRS-2 in said sample.
Patent NZ-583757-A (NZ)
Title: Ophthalmic compositions which comprise erythritol, carnitine and a ionically charged cellulose polymer
Inventor: VEHIGE JOSEPH G
IPC: A61K9/08
Filed: 2005-11-14
Abstract: Disclosed is a topical ophthalmic composition for the treatment of dry eye comprising: an aqueous carrier; erythritol, its isomers or suitable salts thereof; carnitine, its isomers or suitable salts thereof; and an ionically charged polymeric material selected from the group consisting of carboxymethyl cellulose and mixtures of carboxymethyl cellulose compounds. Further disclosed is an artificial tear for treating dry eye by providing osmoprotection to the ocular surface comprising: erythritol, its isomers or suitable salts thereof; carnitine, its isomers or suitable salts thereof; carboxymethylcellulose; and water.
Patent NZ-585587-A (NZ)
Title: Retinoid prodrug compound
Inventor: MURATAKE HIDEAKI
IPC: C07C235/88
Filed: 2007-10-31
Abstract: Disclosed is a retinoid prodrug compound represented by the following general formula (I) having a property of being converted into a retinoid after absorption in a living body, which, per se, has substantially no retinoid action, or has weak retinoid action, but is converted into a potent retinoid by an enzymatic chemical modification after absorption in a living body.
Patent NZ-586047-A (NZ)
Title: Anti-vascular endothelial growth factor antibodies
Inventor: FUH GERMAINE
IPC: A61K39/395
Filed: 2008-12-01
Abstract: An anti-vascular endothelial growth factor (VEGF) antibody. The antibody comprises the heavy chain hypervariable regions HVR-H1, HVR-H2 and HVR-H3 encoded by SEQ ID NOs: 1, 2 and 3 respectively and the light chain hypervariable regions, HVR-L2 and HVR-L3 encoded by SEQ ID NO: 6 and 7 respectively and the HVR-L1 encoded by SEQ ID NOs: 4 or 5. The antibody can be used for inhibiting angiogenesis or vascular permeability and for the treatment of a tumour, cancer or cell proliferative disorder.
Patent NZ-589985-A (NZ)
Title: Novel canola protein isolate
Inventor: SCHWEIZER MARTIN
IPC: A23J1/14
Filed: 2009-06-20
Abstract: Provided is a process for the preparation of a canola protein isolate having an increased proportion of 2S canola protein, which includes: (a) providing an aqueous solution of 2S and 7S proteins consisting predominantly of 2S protein, (b) isoelectrically precipitating 7S protein from the aqueous solution, (c) removing precipitated 7S protein from the aqueous solution, and (d) recovering a canola protein isolate having a protein content of at least 90 wt% (N x 6.25) d.b. and having an increased proportion of 2S canola protein compared to the aqueous solution of 2S and 7S proteins. The isolated protein can be used in soft drinks and sports drinks.
Patent NZ-591383-A (NZ)
Title: Combination full-duplex and half-duplex electronic identification tag
Inventor: STEWART ROBERT
IPC: G06K19/07
Filed: 2009-09-04
Abstract: 591383 Disclosed is an identification tag, configured to respond to interrogation cycles that include intervals in which an activation signal is present, and intervals in which the activation signal is absent. The tag has an inductive antenna (501) including two terminals connected to tag circuitry (500). The inductive antenna (501) forms a resonant antenna circuit tuned to resonate at the frequency of the activation signal. The tag circuitry (500) includes a non-volatile memory (511c) and is configurable, alongside the resonant antenna circuitry, as an oscillator. The tag circuitry (500) is configured to be powered by electric current induced in the resonant antenna circuit by the activation signal. The tag circuitry (500) also has at least one switchable load impedance (520) connected across the antenna resonant circuit and is configurable to amplitude modulate the activation signal appearing at the resonant antenna circuit terminals using the switchable load impedance (520). The tag circuitry (500) is configurable to frequency shift key modulate the oscillator signal appearing at the resonant antenna circuit terminals using the switchable load impedance (520) during intervals in which the activation signal is not present. The activation signal is amplitude modulated with a sequence indicative of full-duplex identification data and transmits a frequency shift keyed signal indicative of half-duplex identification data during the interrogation of the tag.
Patent NZ-594510-A (NZ)
Title: Compositions and methods for the treatment of infections and tumors
Inventor: SHARPE ARLENE
IPC: A61K39/00
Filed: 2007-12-26
Abstract: The use of a Programmed Death (PD-1) antagonist and a tumour antigen for treating a mammalian subject having a tumour. The antagonist can be an anti-PD1 antibody, an anti-Programmed Death Ligand 1 (PD-L1) or an anti-PD-L2 antibody; a siRNA or antisense RNA directed to PD-1, PD-L1 or PD-L2; or a dominant negative PD-1, PD-L1 or PD-L2 protein. The tumour antigen can be PRAME, WT1, surviving, cycin D, cyclin E, proteinase 3 and its peptide PR1, neutrophil elastase, cathepsin G, MAGE, MART tyrosinase, GP100, MY-Eso-1, Herceptin, carcino-embryonic antigen (CEA) or prostate specific antigen (PSA).
Patent NZ-596845-A (NZ)
Title: Carbon oxides conversion process
Inventor: PARK COLIN WILLIAM
IPC: B01J37/12
Filed: 2010-05-24
Abstract: 596845 A carbon oxides conversion process is described, which comprises reacting a carbon oxide containing process gas containing hydrogen and/or steam and containing at least one of hydrogen and carbon monoxide in the presence of a catalyst comprising shaped units formed from a reduced and passivated catalyst powder said powder comprising copper in the range 15 70 % by weight, zinc oxide wherein the weight ratio of Cu:Zn expressed as oxide is ?1:1, alumina in the range 5-60 % by weight and optionally one or more oxidic promoter compounds selected from compounds of Mg, Cr, Mn, V, Ti, Zr, Ta, Mo, W, Si and rare earths in the range 0.01 - 10 % by weight, wherein said shaped units have a reduced to as-made mean horizontal crush strength ratio of ?0.5: 1 and a copper surface area above 60m2/g Cu.
Patent NZ-598170-A (NZ)
Title: Pharmaceutical compositions comprising bi-1356 and metformin
Inventor: MEINICKE THOMAS
IPC: A61K31/155
Filed: 2010-10-01
Abstract: Disclosed is a use of a pharmaceutical composition comprising or made from a DPP-4 inhibitor which is 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, and metformin; a stabilizer which is a nucleophilc and/or basic agent, a buffering agent or a pH modifying agent which is L-arginine, and one or more pharmaceutical excipients; for preparing a medicament for use in treating and/or preventing (including slowing the progression and/or delaying the onset) of metabolic diseases, especially type 2 diabetes mellitus and conditions related thereto (e.g. diabetic complications), either in type 2 diabetes patients who have not been previously treated with an antihyperglycemic agent, or in type 2 diabetes patients with insufficient glycemic control despite therapy with one or two conventional antihyperglycemic agents selected from metformin, sulphonylureas, thiazolidinediones (e.g. pioglitazone), glinides, alpha-glucosidase blockers, GLP-1 or GLP-1 analogues, and insulin or insulin analogues; optionally in combination with one or more other active substances.
Patent NZ-600133-A (NZ)
Title: Systems and methods for assessing the authenticity of dynamic handwritten signature
Inventor: DINESCU ADRIAN
IPC: G06F3/0354
Filed: 2010-10-21
Abstract: Disclosed is a system for acquisition and processing data associated to dynamic handwritten signature, made on writing paper support or any other support with similar texture having quasi-uniform pattern printed thereon. The system includes an electronic pen provided with two groups of inertial acceleration sensors MEMS (A), (B), to capture kinetic data ax, ay, bx, by and data about the writing support contact micro vibrations, integrated into a personal computer for the acquisition and processing of the signals associated to the signatures. The personal computer can be network connected with other personal computers, each one having connected as peripherals an electronic pen. The electronic pen includes a self-referential optical navigation sensor (ONS) for capturing the series of data pairs dx, dy, as momentary movements necessary for the reconstruction of pen's trajectory. The trajectory together with the kinetic data ax, ay, bx, by captured by a set of inertial sensors MEMS (A) and (B) constitute personal computer input data for sensorial fusion processing and for creating the conditions to extract the information from the sensorial and psychometric representation of the user's perspective. The pen also includes an infrared (IR) LED to illuminate the pattern and a lens (L) for focusing and current image projection of the pattern on the sensitive area of an optical navigation sensor (ONS). The lens (L) is positioned so that the projection of a pattern region image is to be obtained on the sensitive area of the sensor. The acquisition through sensorial fusion of the two data categories dx, dy of graphic type and ax, ay, bx, by accelerations require a condition of spatial temporal synchronism. This is achieved by axial and topological quasi-alignment of the three origins of the coordinate axes of the MEMS sensors (A and B); of optical navigation sensor (ONS) and of pen's refill tip; topological plane-parallel quasialignment of coordinate/sensitive axes of the three sensorial components MEMS (A), (B) and of the optical navigation sensor (ONS) with the writing plane (P); and by the sampling of data captured by sensors, with a constant rate, ranging between 1-8 ms which assure the time synchronism of the acquisition of graphic and kinetic details. The acquisition is controlled by an acquisition microcontroller (uCA) which sends the information in real time to the personal computer that hosts the algorithmic methods for visualization, for writing thickness reconstruction and for processing and comparison. In order to capture the data from the psychometric and sensorial representation from user's perspective, the set of sensors MEMS (A), (B) and the optical navigation sensor (ONS), integrated in the writing device handled by the user, capture the six associated signals ax, ay, bx, by, dx, dy in self-referential coordinate systems, respectively the own x, y co-ordinates axes of sensitivity.
Patent NZ-600208-A (NZ)
Title: Inhalation solutions
Inventor: LULLA AMAR
IPC: A61K9/12
Filed: 2010-11-17
Abstract: Disclosed is an inhaler (10) for an inhalation formulation (14). The inhaler (10) is comprised of a canister (12) containing a pharmaceutical composition (14) under pressure, a metering valve (18), and an actuator (22). The metering valve (18) measures a metered dose of the composition (14) from the canister (12) for administration to a patient in need thereof. The actuator (22) actuates discharge of the metered dose to the patient. The actuator (22) includes a discharge orifice (28) having a diameter in the range 0.2 to 0.4 mm. The pharmaceutical composition (14) comprises an anticholinergic agent and a pharmaceutically acceptable propellant. The metered dose contains 2.5 micrograms to 18 micrograms of the anticholinergic agent.
Patent NZ-601163-A (NZ)
Title: Screen panel with wear protective apertures
Inventor: MOHANKA MADAN MOHAN
IPC: B07B1/46
Filed: 2010-09-13
Abstract: An ore screening panel for the mining and quarrying industries is adapted to be mounted on a screen deck, and includes an aperture screen of resilient material mounted on a reinforcing frame. The apertures allow materials of predetermined size to pass through, and the walls of the apertures are lined with linings of abrasion resistant material, either of metal or ceramic or refractory silicon carbide compound. The linings have a plurality of slits cut along the vertical as well as horizontal line in the top and bottom portions of the linings, so that at least first and second slits are separated by portions of the linings extending vertically between the slits, whereby utmost flexibility of the apertures is ensured whilst simultaneously ensuring wear protection.
Patent NZ-603621-A (NZ)
Title: Patient interface systems
Inventor: CARROLL FIONA CATHERINE
IPC: A61M16/06
Filed: 2008-10-22
Abstract: 603621 A seal positioning and stabilizing structure for a patient interface structure for delivery of a supply of air at positive pressure to the entrance of a patient’s airways for treatment of sleep disordered breathing, the sealing positioning and stabilizing structure being arranged in use to direct a tension force to a region adjacent an underside of a patient’s nose at the entrance of a patient’s airways to effect a seal therewith. The seal positioning and stabilizing structure comprises: a flexible moulded strap (74l) having a first portion adapted to be positioned adjacent a temple region in use and a second portion adapted to be positioned adjacent a cheek region in use, wherein the first portion and the second portion are moulded in one piece to define an angle (B) therebetween in the range of about 150 degrees to about 90 degrees. The seal positioning and stabilizing structure is moulded to further comprise a stiffened portion located between the first and the second portions. The seal positioning and stabilizing structure further comprises a rear strap (85) adapted to pass around a rear of a patient’s head in use.
Patent NZ-615071-A (NZ)
Title: Cycloalkenyl aryl derivatives for cetp inhibitor
Inventor: LEE SEOHEE
IPC: C07D413/06
Filed: 2012-04-12
Abstract: Disclosed are compounds of formula I where the substituents are as defined herein. The compounds are cycloalkenyl aryl oxazolidinone or oxazolidine thione derivatives, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof, an example is (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxyphenyl)-5,5-dimethylcyclohexl-enyl)methyl)-4-methyloxazolidin-2-one. Also disclosed are methods for preparing the compounds and pharmaceutical compositions containing the same. The compounds of the present invention show the effect of CETP activity inhibition and therefore the compounds can increase HDL-cholesterol and decrease LDL-cholesterol.
Patent NZ-615441-A (NZ)
Title: Humanised antibodies to toll-like receptor 2 and uses thereof
Inventor: DELLACASAGRANDE JEROME
IPC: C12N15/13
Filed: 2010-07-06
Abstract: Disclosed is an isolated monoclonal antibody, or antigen binding portion thereof, which binds an epitope on human Toll-like Receptor 2 with a KD of 3x10-8 M or less and which mediates TLR2 antagonism independent of binding of the antibody or the antigen binding portion thereof to CD32 (Fc gamma receptor II), wherein the epitope (SEQ ID NO: 13 KEESSNQASLSCDRNGICKGS and SEQ ID NO: 14 CSCEFLSFTQEQQ) is recognised by a reference antibody and wherein that reference antibody is comprised of SEQ ID NO:4 or 5 and SEQ ID NO: 1 or 2.
Patent NZ-618711-A (NZ)
Title: A tool block for holding a tool
Inventor: JEREMY ROBERT KANE KENEALY
IPC: B21D28/34
Filed: 2013-02-08
Abstract: A tool block (1) for holding a tool. The tool block has a u-shaped body with parallel first and second arms. A slot (2) runs between the arms. There is an aperture (6a) in the first arm which extends to the slot (2). The aperture (6a) is located towards the outer end of the arm. The aperture is shaped to receive and hold a stationary tool in use. The tool block has a groove (7) formed between the outer end and inner side of the first arm. The groove (7) passes through the outer end of the first arm to the aperture. The tool block has a grub screw hole (18) on the first arm. The grub screw hole (18) passes from the exterior of the first arm through to the first arm aperture. The grub screw hole (18) is threaded to receive a grub screw to hold the stationary tool in position.
Patent NZ-629974-A (NZ)
Title: Electrolysis apparatus
Inventor: JACOBS GIDEON JOHANNES
IPC: C25B1/04
Filed: 2013-09-05
Abstract: Disclosed is an apparatus (100) for performing electrolysis and generating heat. The apparatus (100) includes an electrolysis cell (110) with a cell housing (111) defining an electrolyte cavity containing an electrolyte (113) in use and also includes a plurality of substantially parallel spaced apart electrode plates (115) provided within the electrolyte cavity and at least two connectors (116), which in use are connected to an electrical power supply thereby allowing an electrical current to be supplied to the electrolyte (113) to perform electrolysis and heating of the electrolyte (113). At least one cell outlet (125) coupled to a heat recovery module is in fluid communication with the electrolyte cavity, and at least one cell inlet (124) allows the electrolyte (113) to be supplied to the electrolyte cavity. The apparatus (100) also includes a trigger circuit coupled to the at least two connectors (116), a switch, and a load coupled to the at least two connectors (116) via the switch. The trigger circuit selectively activates the switch to thereby couple the at least two connectors (116) to the load.
Patent NZ-630930-A (NZ)
Title: Medicine container, method of assembling the container, and method of dispensing the medicine from the container
Inventor: JOHN FINCH
IPC: B65D83/04
Filed: 2014-07-03
Abstract: Disclosed is a child-resistant medication dispensing container assembly with additional information about the use of the medicament displayed on the package. The package assembly comprises a blister pack including a plurality of compartments, each of the plurality of compartments configured to support at least one medication; a puck including a recess having a plurality of openings with each opening in the puck corresponding to one of the plurality of compartments of the blister pack; and a box including a first wall opposite a second wall. A plurality of openings extend through the first wall, each of the openings in the first wall being aligned with corresponding perforations in the second wall, each of the openings in the first wall being aligned with one of the openings in the puck and a corresponding compartment of the blister pack. Each of the plurality of compartments is spaced apart from the complementary opening in the box. A series of instructions for administering the medication is secured within the plurality of compartments of the blister pack.
Patent NZ-702269-A (NZ)
Title: Improved antagonist antibodies against gdf-8 and uses therefor
Inventor: APGAR JAMES REASONER
IPC: C07K16/22
Filed: 2013-06-12
Abstract: The disclosure provides improved neutralizing anti-GDF-8 antibodies capable of substantially higher levels of expression in host cells compared to previous anti-GDF-8 antibodies. Also provided are methods of using compositions comprising such antibodies to increase muscle mass or strength, and to treat or prevent muscular disorders, neuromuscular disorders, metabolic disorders, adipose tissue disorders or bone disorders.
Patent NZ-703563-A (NZ)
Title: Air freshener
Inventor: LESNIAK FRANK M
IPC: A61L9/12
Filed: 2013-04-30
Abstract: An air freshener removably engages with a structure, such as the supporting post of a rear view mirror of a motor vehicle. The air freshener has a rigidifying core defining a central axis, and an outer portion or sleeve contacting the core that is formed from one or more fragrance loaded polymers. Together, the core and outer portion are shaped to surround a first axis perpendicular to the central axis. The ends of the air freshener are juxtaposed generally opposite one another in closed configuration, and the arm portions of the air freshener flex in directions substantially parallel to the first axis to separate the ends to open the air freshener. A breakable strap and/or connectors may be provided to join the ends together. Alternatively, one end of the air freshener may be inserted within a cavity formed in the opposite end of the air freshener.
Patent NZ-714208-A (NZ)
Title: Treatment of coal
Inventor: PONCE DE LEON INGNACIO
IPC: F23C1/04
Filed: 2014-05-30
Abstract: A problem to be solved by the present disclosure is to reduce the emission of undesired pollutants during the combustion of coal. The present disclosure provides a process for treating coal by removing moisture and volatile matter from the coal. Air-borne emissions from the combustion of the fuel product of the invention will be cleaner than those of untreated coal and may obviate post combustion or scrubbing technologies that are typically needed to clean the emissions from a coal-fired burner. The disclosed process provides a less costly solution to the problem of dirty emissions than present techniques. A disclosed process of producing a treated coal and combusting the treated coal involves heating the coal to remove volatiles and drying the product to produce a treated coal consisting essentially of carbon and hydrogen, and combusting the treated coal by introducing a slipstream of natural gas alongside the treated coal in a quantity sufficient to sustain a stable burn in an industrial boiler configured to burn bituminous coals.
Patent NZ-750189-A (NZ)
Title: Use of phenoxypropylamine compounds to treat depression
Inventor: PELLEGRINI LORENZO
IPC: A61K31/496
Filed: 2014-01-24
Abstract: Disclosed herein are compositions and methods for treating depression and/or the symptoms of depression using compositions comprising phenoxypropylamine compounds and derivatives having selective affinity for and antagonistic activity against the 5-HT1A receptor, as well as 5-HT reuptake inhibitory activity. Specifically, the oral administration of a compound of formula (M1) or a pharmaceutically acceptable salt, hydrate or solvate thereof to treat or improve at least one sleep disorder or parameter of sleep is described.